Valneva announced today that an End Of Phase 2 meeting has been scheduled with the U.S. Food and Drug Administration on February 24, 2020 for its single-shot chikungunya vaccine candidate, VLA1553.
Valneva announced today that an End Of Phase 2 meeting has been scheduled with the U.S. Food and Drug Administration on February 24, 2020 for its single-shot chikungunya vaccine candidate, VLA1553.